Gout
Conference Coverage
CPPD nomenclature is sore subject for gout group
G-CAN hopes to standardize terminology and finally oust ‘pseudo’ vernacular.
Conference Coverage
Gout: Studies support early use of urate-lowering therapy, warn of peripheral arterial disease
Urate-lowering drugs might be OK early on; gout may boost peripheral arterial disease.
News from the FDA/CDC
Approximately 20% of U.S. adults are diagnosed with arthritis
New data show disproportionate arthritis prevalence among women, veterans, non-Hispanic White individuals, and those aged 45 years and older.
From the Journals
Adverse event rates compared for colchicine, NSAIDs when starting allopurinol for gout
Patients receiving prophylactic colchicine or NSAIDs with initiation of allopurinol for gout have more adverse events than those who receive no...
From the Journals
Colchicine still needed to prevent gout flares in allopurinol ‘start-low, go-slow’ strategy
Patients taking colchicine had fewer gout flares than did those taking placebo for the first 6 months, but the number evened out between the two...
From the Journals
Diabetes drug class appears to reduce recurrent gout flares
Previously associated with a lower incidence of gout, SGLT2 inhibitors for the first time also appear to reduce gout flare recurrence and excess...
News from the FDA/CDC
FDA approves canakinumab for gout flares
Canakinumab is the first biologic in the U.S. approved for treating gout flares.
Latest News
Gout: Suboptimal management a continuing problem
Pipeline drugs show promise but undertreatment, poor adherence reduce efficacy of current therapies.
From the Journals
SGLT2 inhibitors linked with fewer gout flares in diabetes
“SGLT2 inhibitors may offer distinct benefits,” making the drug class “a particularly attractive addition to current urate-lowering therapies.”
Feature
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
Experts in rheumatology, dermatology, and gastroenterology assess the potential of colchicine 0.5 mg to treat residual risk for atherosclerotic...
Guidelines
EULAR issues imaging recommendations for crystal-induced arthropathies
The document provides guidance on using imaging in both the diagnosis and management of all common forms of crystal-induced arthropathies.